Knowledge Management System Of Institute of process engineering,CAS
| A SARS-CoV-2 vaccine based on conjugation of SARS-CoV-2 RBD with IC28 peptide and mannan | |
| He, Yunxia1,2; Yu, Weili1; Shen, Lijuan1; Yan, Wenying1,2; Xiao, Lucheng1,2; Qi, Jinming1; Hu, Tao1 | |
| 2022-12-01 | |
| Source Publication | INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
 |
| ISSN | 0141-8130 |
| Volume | 222Pages:661-670 |
| Abstract | SARS-CoV-2 is a particularly transmissible virus that causes a severe respiratory disease known as COVID-19. Safe and effective vaccines are urgently needed to combat the COVID-19 pandemic. The receptor-binding domain (RBD) of SARS-CoV-2 spike protein elicits most neutralizing antibodies during viral infection and is an ideal antigen for vaccine development. In particular, RBD expressed by E. coli is amenable to low cost and high-yield manufacturability. The adjuvant is necessitated to improve the immunogenicity of RBD. IC28, a TLR5dependent adjuvant, is a peptide from bacterial flagellin. Mannan is a ligand of TLR-4 or TLR-2 and a polysaccharide adjuvant. Here, IC28 and mannan were both covalently conjugated with RBD from E. coli. The conjugate (RBD-IC28-M) elicited high RBD-specific IgG titers, and a neutralization antibody titer of 201.4. It induced high levels of Th1-type cytokines (IFN-gamma) and Th2-type cytokines (IL-5 and IL-10), along with high antigenicity and no apparent toxicity to the organs. The mouse sera of the RBD-IC28-M group competitively interfered with the interaction of RBD and ACE2. Thus, conjugation with IC28 and mannan additively enhanced the humoral and cellular immunity. Our study was expected to provide the feasibility to develop an affordable, easily scalable, effective vaccine SARS-CoV-2 vaccine. |
| Keyword | SARS-CoV-2 RBD Adjuvant |
| DOI | 10.1016/j.ijbiomac.2022.09.180 |
| Language | 英语 |
| WOS Keyword | COVID-19 ; PROTEIN ; IMMUNOGENICITY |
| Funding Project | Beijing Natural Science Foundation ; National Natural Science Foundation of China ; National Key Research and Develop- ment Project of China ; [M21013] ; [82271869] ; [31970875] ; [2018YFA0900804] |
| WOS Research Area | Biochemistry & Molecular Biology ; Chemistry ; Polymer Science |
| WOS Subject | Biochemistry & Molecular Biology ; Chemistry, Applied ; Polymer Science |
| Funding Organization | Beijing Natural Science Foundation ; National Natural Science Foundation of China ; National Key Research and Develop- ment Project of China |
| WOS ID | WOS:000876880400005 |
| Publisher | ELSEVIER |
| Citation statistics | |
| Document Type | 期刊论文 |
| Identifier | http://ir.ipe.ac.cn/handle/122111/55473 |
| Collection | 中国科学院过程工程研究所 |
| Corresponding Author | Qi, Jinming; Hu, Tao |
| Affiliation | 1.Chinese Acad Sci, State Key Lab Biochem Engn, Inst Proc Engn, Beijing 100190, Peoples R China 2.Univ Chinese Acad Sci, Beijing 100190, Peoples R China |
| Recommended Citation GB/T 7714 | He, Yunxia,Yu, Weili,Shen, Lijuan,et al. A SARS-CoV-2 vaccine based on conjugation of SARS-CoV-2 RBD with IC28 peptide and mannan[J]. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES,2022,222:661-670. |
| APA | He, Yunxia.,Yu, Weili.,Shen, Lijuan.,Yan, Wenying.,Xiao, Lucheng.,...&Hu, Tao.(2022).A SARS-CoV-2 vaccine based on conjugation of SARS-CoV-2 RBD with IC28 peptide and mannan.INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES,222,661-670. |
| MLA | He, Yunxia,et al."A SARS-CoV-2 vaccine based on conjugation of SARS-CoV-2 RBD with IC28 peptide and mannan".INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES 222(2022):661-670. |
| Files in This Item: | There are no files associated with this item. | |||||
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.
Edit Comment